10x Genomics, Inc. provided revenue guidance for full year 2022. For the period, the company expects revenue guidance of $500 million to $520 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.45 USD | -2.02% | -0.97% | -65.24% |
28/06 | Barclays Cuts Price Target on 10x Genomics to $24 From $36, Maintains Overweight Rating | MT |
27/06 | Wolfe Research Downgrades 10x Genomics to Peer Perform From Outperform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.24% | 2.33B | |
-11.78% | 11.24B | |
-13.76% | 7.29B | |
+29.50% | 5.57B | |
-0.19% | 5.31B | |
-19.19% | 3.68B | |
+7.62% | 2.58B | |
-10.48% | 2.23B | |
+27.80% | 2.21B | |
-19.12% | 1.57B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10X Genomics, Inc. Provides Revenue Guidance for Full Year 2022